ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,970.84
-1.11%
US Tech 100
20,897.20
-1.35%
다우존스 지수
42,992.21
-0.77%
Bitcoin
93,368.97
-0.16%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Xilio Therapeutics Inc (XLO)

  7. Xilio Therapeutics Inc (XLO) 뉴스

Xilio Therapeutics Inc

Xilio Therapeutics Inc (XLO)

NASDAQ
0.9722
-0.0028
(-0.29%)
마감 30 12월 6:00AM
15분 지연
0.9722
0.00
(0.00%)
시간외 거래: 9:21AM
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

XLO 뉴스

공식 뉴스 전용

Form 8-K - Current report
Edgar (US Regulatory)
19 12월 2024
XLO (-0.29%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
07 11월 2024
XLO (-0.29%)

Form 8-K - Current report
Edgar (US Regulatory)
07 11월 2024
XLO (-0.29%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
03 10월 2024
XLO (-0.29%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
28 9월 2024
XLO (-0.29%)

XLO Discussion

게시물 보기
tbonaces80 tbonaces80 1 주 전

Here it is
👍️0
tbonaces80 tbonaces80 1 주 전
Bullish pennant on continuation. Thank me later
👍️ 2
tbonaces80 tbonaces80 1 주 전
Strike is easily $1.97. News or approval and we go hard
👍️0
tbonaces80 tbonaces80 1 주 전
Loaded a nice position here
👍️0
Preciouslife1 Preciouslife1 1 주 전
https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-present-initial-phase-2-data-vilastobart
👍 1
PonkenPlonken PonkenPlonken 4 주 전
trades below cash value
Makes no f in sense!
stick it out......
👍️ 1
Preciouslife1 Preciouslife1 2 월 전
https://ir.xiliotx.com/news-releases/news-release-details/xilio-therapeutics-announces-initial-clinical-trial-data-phase
👍️0
TrendTrade2016 TrendTrade2016 2 월 전
XLO HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 2 월 전
BIO BEAST
👍️0
TrendTrade2016 TrendTrade2016 2 월 전
XLO MONSTER BREAK
👍 1
TrendTrade2016 TrendTrade2016 2 월 전
XLO BUILDING STEAM
👍 1
PonkenPlonken PonkenPlonken 2 월 전
running towards two readouts with Gilead sitting at 17% ownership at 1.97$ strike. I have the hubris to say this WILL GO GO
👍️0
TrendTrade2016 TrendTrade2016 2 월 전
XLO HERE WE GO
👍️0
PonkenPlonken PonkenPlonken 2 월 전
COMING TO LIFE
masked antibodies
👍 1
TrendTrade2016 TrendTrade2016 2 월 전
XLO...MINI BIO BEAST
👍 1
Laster Laster 2 월 전
Got some at $1.00 several days ago.
I like the share structure. It might run for a few days.
Looking for $1.40 if I am lucky.
👍️ 1
Preciouslife1 Preciouslife1 2 월 전
https://ir.xiliotx.com/news-and-events/news-releases
👍️ 1
Preciouslife1 Preciouslife1 3 월 전
https://www.linkedin.com/posts/hashem-al-ghaili-1b30679b_drug-resistant-bacteria-are-projected-to-activity-7246464071565201410-sAL9?utm_source=share&utm_medium=member_ios
👍️0
Preciouslife1 Preciouslife1 4 월 전
This information makes one wonder IF BRILICIDIN IS BEING SUPPRESSED TOO: https://www.facebook.com/share/r/MTAzjcdR5iGnab4t/?mibextid=6GsUZ4
👍️ 1
Preciouslife1 Preciouslife1 4 월 전
https://www.gilead.com/news-and-press/press-room/press-releases/2024/3/gilead-and-xilio-announce-exclusive-license-agreement-for-tumor-activated-il-12-program
👍️0
PonkenPlonken PonkenPlonken 4 월 전
Gilead paid 13.5mn$ @ 1.97
The results of their partnered program and another one will be reported in Q4 24
masked antibodies... very little toxicity.
I have a small position... Think big rally coming into 2025- atleast to the 1.97 strike.


"Under the License Agreement, the Company will receive approximately $43.5 million in upfront payments, including a cash payment of $30.0 million and an initial equity investment by Gilead of approximately $13.5 million in the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at a purchase price of $1.97 per share. The Company will be eligible to receive up to $604.0 million in additional contingent payments, which include (i) the proceeds from up to three additional private placements of Common Stock, (ii) the $75.0 million transition fee and (iii) specified development, regulatory and sales-based milestones. Prior to the potential transition fee, up to $29.0 million of the total contingent payments are related to the potential additional private placements of Common Stock and a near-term development milestone. In addition, the Company is eligible to receive tiered royalties ranging from high single digits to mid-teens on annual global net product sales."

"In addition, through March 27, 2025, the Company may, at its election and subject to the terms and conditions of the Stock Purchase Agreement, cause Gilead to purchase up to approximately $11.5 million of additional shares of Common Stock (including, at Gilead’s sole election, prefunded warrants in lieu of shares of Common Stock) in up to three additional private placements (each, an “Additional Gilead Private Placement”) at a predetermined price per share..."
👍️ 1
PonkenPlonken PonkenPlonken 7 월 전
XLO -- unique masking approach and great results. Hot field $JANX. Gilead certainly thinks so - buys real equity. Company trades below the upfront payment...

https://schrts.co/tdtYZDEX
👍️0
Preciouslife1 Preciouslife1 7 월 전
Hi I tried to buy a bunch of shares this morning once at .885 then at .90; never filled though over the ASK PRICE then it took off upwards! MM MANIPULATION MUCH!?!?
👍️0
Laster Laster 8 월 전
Stock closed the gap. They are in the right biotech area similar to CLRB and CTMX and SNSE.
Only a matter of time before this explodes to $2 or higher.
JMO.
👍️0
Monksdream Monksdream 8 월 전
XLO under $2
👍️0
Laster Laster 8 월 전
The chart shows a very nice looking pennant pattern.
Biotechs are not trading well recently.
Any recovery in biotechs then this could get interesting.
Needs to move past $1.50 to confirm breakout.
Enjoy the day.
👍️0
Laster Laster 9 월 전
I remember when OCEA had similar pennant pattern before it broke out to $7.50.
Crazy times sometimes causes crazy moves.
I like the story here. Seems like a nice biotech to invest into.
JMO.
Enjoy.
👍️0
Laster Laster 9 월 전
Oops. I blinked. Missed it.
Maybe I will be quicker when it moves back to $1.20.
Unless it pops to $1.50 on no news.
Chart looks interesting. Nice pennant pattern.
Enjoy.
👍️0
Awl416 Awl416 9 월 전
Don’t blink
👍️0
Invest-in-America Invest-in-America 9 월 전
XLO: Best of luck on this one, Capt. TIm!! (I DID get both of your Post-M iHub 'emails', so I am answering both of them vis-a-vis this single one.) I am still in SHOCK that XLO did NOT soar at least 400% today.

WILD, UNPREDICTABLE, DAY TODAY!!! (And I missed all the glory behind @AVTX, to boot!! BUMMER!!!)
👍️0
TIMGZ TIMGZ 9 월 전
XLO IS MOVING , HOPEFULLY THE TORTOISE-LIKE CONTINUES*****
IN THE NEXT 3 HOURS AND PR MONDAY SHOULD BE MORE GLORIOUS****WE SHALL SEE***


THAT WAS AN EXCELLENT PR BUT THE PLAN ALL ALONG WAS SNAKE-OIL-LIKE
👍️0
Invest-in-America Invest-in-America 9 월 전
XLO: Worthless piece of SHIT!!!
👍️0
Invest-in-America Invest-in-America 9 월 전
XLO: Oooooooo, Boy!!! (Latest 'Chart', below, looks pretty good!!!)




"I gots my entire weekly ALLOWANCE in this, sucka!!! So you BETTER gets to Planet Jupiter pretty damn QUICK!!!"
👍️0
Invest-in-America Invest-in-America 9 월 전
XLO: Halted.
👍️0
JPetroInc JPetroInc 9 월 전
nice news on XLO

looks a lot like iBio news

good fortunes to all XLO shareholders …

EOM
👍️0
Awl416 Awl416 9 월 전
Watch out for these dirty algo’s
👍️0
Awl416 Awl416 9 월 전
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
👍️0
Awl416 Awl416 9 월 전
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
👍️0
crudeoil24 crudeoil24 3 년 전
Price target > 36.00 > HC Wainwright & Co. analyst Michael King initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Buy rating and announces Price Target of $36.

Latest Ratings for XLO DateFirmActionFromTo

Jan 2022HC Wainwright & Co.Initiates Coverage OnBuy Nov 2021Raymond JamesInitiates Coverage OnOutperform Nov 2021Cowen & Co.Initiates Coverage OnOutperform

👍️0
crudeoil24 crudeoil24 3 년 전
TODAY > Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Rene Russo, Pharm. D., president and chief executive officer, and Marty Huber, M.D., president of research and development and chief medical officer of Xilio Therapeutics, will participate in a virtual fireside chat during the Guggenheim 4 Annual Oncology Day on Thursday, February 10, 2022, at 8:30 a.m. ET.

A live webcast will be available in the Investors and Media section of the Xilio Therapeutics' website at https://ir.xiliotx.com. A replay of the webcast will be archived on Xilio Therapeutics' website for 30 days following the presentation.
👍️0
crudeoil24 crudeoil24 3 년 전
Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity
👍️0

최근 히스토리

NASDAQ
XLO
Xilio Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유